Evidence map›Paper›PMID 26868851›Full record

ArticleTechnology in cancer research & treatment2017

miR-139 Functions as An Antioncomir to Repress Glioma Progression Through Targeting IGF-1 R, AMY-1, and PGC-1β.

Hong Wang, Xi Yan, Li-Ya Ji, Xi-Tuan Ji, Ping Wang, Shi-Wen Guo, San-Zhong Li

Open access · bronzeAbstract read
In one paragraph

Article in Technology in cancer research & treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.0field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hong Wang1 Department of Neurosurgery, the First Affiliated Hospital of Xi'an Jiaotong, University College of Medicine, Xi'an, China.
Xi Yan3 Department of Internal Medicine, Xi'an Dongfang Hospital.
Li-Ya Ji4 Department of Neurology, the Affiliated Xi'an Central Hospital of Xi'an Jiaotong, University College of Medicine, Xi'an, China.
Xi-Tuan Ji5 Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Ping Wang2 Department of Neurosurgery, the Affiliated Xi'an Central Hospital of Xi'an Jiaotong University College of Medicine, Xi'an, China.
Shi-Wen Guo1 Department of Neurosurgery, the First Affiliated Hospital of Xi'an Jiaotong, University College of Medicine, Xi'an, China.
San-Zhong Li5 Department of Neurosurgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
First Affiliated Hospital of Xi'an Jiaotong University · CNAir Force Medical University · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gliomas are the most common primary malignant brain tumor with poor prognosis, characterized by a highly heterogeneous cell population, extensive proliferation, and migration. A lot of molecular mechanisms regulate gliomas development and invasion, including abnormal expression of oncogenes and variation of epigenetic modification. MicroRNAs could affect cell growth and functions. Several reports have demonstrated that miR-139 plays multifunctions in kinds of solid tumors through different pathways. However, the antitumor mechanisms of this miR-139 are not unveiled in detail. In this study, we not only validated the low expression level of miR-139 in glioma tissues and cell lines but also detected the effect of miR-139 on modulating gliomas proliferation and invasion both in vitro and in vivo. We identified insulin-like growth factor 1 receptor, associate of Myc 1, and peroxisome proliferator-activated receptor γ coactivator 1β as direct targets of miR-139 and the levels of them were all inversely correlated with miR-139 in gliomas. Insulin like growth factor 1 receptor promoted gliomas invasion through Akt signaling and increased proliferation in the peroxisome proliferator-activated receptor γ coactivator 1β-dependent way. Associate of Myc 1 also facilitated gliomas progression by activating c-Myc pathway. Overexpression of the target genes could retrieve the antitumor function of miR-139, respectively, in different degrees. The nude mice transplantation tumor experiment displayed that glioma cells stably expressed miR-139 growth much slower in vivo than the negative control cells. Taken together, these findings suggested miR-139 acted as a favorable factor against gliomas progression and uncovered a novel regulatory mechanism, which may provide a new evidenced prognostic marker and therapeutic target for gliomas.

Indexed as

Gene Expression Regulation, NeoplasticAnimalsBase SequenceBinding SitesBrain NeoplasmsCarrier ProteinsCell Line, TumorCell MovementCell ProliferationDisease ProgressionDNA-Binding ProteinsGene ExpressionGenes, Tumor SuppressorGliomaHumansMaleCarrier ProteinsDNA-Binding ProteinsMicroRNAsMIRN139 microRNA, humanMYCBP protein, humanPPARGC1B protein, humanProto-Oncogene Proteins c-aktReceptor, IGF Type 1RNA-Binding ProteinsTranscription FactorsAMY-1gliomaIGF-1 RmiR-139PGC-1βtumor progression

Identifiers

PMID26868851
PMCPMC5616056
OpenAlexW2286680901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.